Tirofiban for the Prevention of Early Neurological Deterioration After Intravenous Thrombolysis in Acute Ischemic Stroke

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 302 participants.

Also called NCT06587347

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 302 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06587347
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06587347. Randomized; single masking; primary purpose treatment. Start 2024-11-20 (anticipated); primary completion 2026-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Tirofiban for the Prevention of Early Neurological Deterioration After Intravenous Thrombolysis in Acute Ischemic Stroke
Acronym
TREND-2
Condition
Acute Stroke
Condition
Ischemic Stroke, Acute
Condition
Cerebral Infarction
Intervention (Drug)
Tirofiban Hydrochloride
Intervention (Drug)
Standard medical treatment (SMT)
Lead sponsor
Capital Medical University (class: other)

Record details

Record id
cardio:ct-nct06587347
Content hash
c54eca1b30d0681e33498f6fb01727ca8223242f939a942b2ffdcb7e25ca2f6e